These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 29263175)

  • 1. Pulmonary arterial hypertension: tailoring treatment to risk in the current era.
    Gaine S; McLaughlin V
    Eur Respir Rev; 2017 Dec; 26(146):. PubMed ID: 29263175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond a single pathway: combination therapy in pulmonary arterial hypertension.
    Sitbon O; Gaine S
    Eur Respir Rev; 2016 Dec; 25(142):408-417. PubMed ID: 27903663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience.
    Sitbon O; Vonk Noordegraaf A
    Eur Respir Rev; 2017 Jan; 26(143):. PubMed ID: 28096285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New horizons in pulmonary arterial hypertension therapies.
    Galiè N; Ghofrani AH
    Eur Respir Rev; 2013 Dec; 22(130):503-14. PubMed ID: 24293466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary hypertension-"state of the art" management in 2012.
    Saxena A
    Indian Heart J; 2012; 64(1):60-73. PubMed ID: 22572428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Future perspectives in pulmonary arterial hypertension.
    Simonneau G; Hoeper MM; McLaughlin V; Rubin L; Galiè N
    Eur Respir Rev; 2016 Dec; 25(142):381-389. PubMed ID: 27903660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension.
    Lang IM; Gaine SP
    Eur Respir Rev; 2015 Dec; 24(138):630-41. PubMed ID: 26621977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical considerations for therapies targeting the prostacyclin pathway.
    Farber HW; Gin-Sing W
    Eur Respir Rev; 2016 Dec; 25(142):418-430. PubMed ID: 27903664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary Arterial Hypertension in Women.
    Memon HA; Park MH
    Methodist Debakey Cardiovasc J; 2017; 13(4):224-237. PubMed ID: 29744015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow?
    Seferian A; Simonneau G
    Eur Respir Rev; 2013 Sep; 22(129):217-26. PubMed ID: 23997048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary arterial hypertension: the burden of disease and impact on quality of life.
    Delcroix M; Howard L
    Eur Respir Rev; 2015 Dec; 24(138):621-9. PubMed ID: 26621976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary hypertension in 2012: contemporary issues in diagnosis and management.
    Lau EM; Corte TJ
    Panminerva Med; 2012 Mar; 54(1):11-28. PubMed ID: 22278113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era.
    Savale L; Guignabert C; Weatherald J; Humbert M
    Eur Respir Rev; 2018 Jun; 27(148):. PubMed ID: 29653948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macitentan for the treatment of pulmonary arterial hypertension.
    Spikes L; Williamson T; Satterwhite L
    Drugs Today (Barc); 2014 Jun; 50(6):401-6. PubMed ID: 24983588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognosis and response to first-line single and combination therapy in pulmonary arterial hypertension.
    Kylhammar D; Persson L; Hesselstrand R; Rådegran G
    Scand Cardiovasc J; 2014 Aug; 48(4):223-33. PubMed ID: 24912571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertension.
    Udeoji DU; Schwarz ER
    Ther Adv Respir Dis; 2013 Feb; 7(1):39-49. PubMed ID: 23129569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of adults with Eisenmenger syndrome treated with drugs specific to pulmonary arterial hypertension: A French multicentre study.
    Hascoet S; Fournier E; Jaïs X; Le Gloan L; Dauphin C; Houeijeh A; Godart F; Iriart X; Richard A; Radojevic J; Amedro P; Bosser G; Souletie N; Bernard Y; Moceri P; Bouvaist H; Mauran P; Barre E; Basquin A; Karsenty C; Bonnet D; Iserin L; Sitbon O; Petit J; Fadel E; Humbert M; Ladouceur M
    Arch Cardiovasc Dis; 2017 May; 110(5):303-316. PubMed ID: 28286190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treat-to-target approach in pulmonary arterial hypertension: a consensus-based proposal.
    Sitbon O; Baloira Villar A; Bauer F; Ekmehag B; Gin-Sing W; Jansson K; Kiely DG; Leuchte H; Manes A; Rosenkranz S; Escribano P
    Eur Respir Rev; 2012 Sep; 21(125):259-62. PubMed ID: 22941892
    [No Abstract]   [Full Text] [Related]  

  • 19. Pathobiology of pulmonary arterial hypertension: understanding the roads less travelled.
    Hemnes AR; Humbert M
    Eur Respir Rev; 2017 Dec; 26(146):. PubMed ID: 29263173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand?
    Correale M; Ferraretti A; Monaco I; Grazioli D; Di Biase M; Brunetti ND
    Vasc Health Risk Manag; 2018; 14():253-264. PubMed ID: 30323613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.